Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.

Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.
复制标题

DOI:
10.1016/j.febslet.2012.03.052
复制
发表时间:
2012-05-21
期刊:
影响因子:
3.5
通讯作者:
Chen X
Chen X
中科院分区:
生物学3区
文献类型:
--
作者:
Jung YS;Qian Y;Chen X

文献摘要

参考文献

被引文献

相似文献

泛素依赖的蛋白酶体系统在许多细胞过程和包括癌症在内的各种人类疾病的发病机制中起着关键作用。虽然有大量的E3泛素连接酶,但大多数是环指型E3。Pirh 2是p53转录因子的靶基因,含有一个高度保守的C3 H2 C3型RING结构域。重要的是,Pirh 2被发现调节一组致力于DNA损伤反应的关键因子,如p53,p73,PolH和c-Myc。有趣的是,Pirh 2在不同类型的癌症中上调或下调。这些表明Pirh 2以组织依赖性方式参与促进或抑制肿瘤进展。本文将重点介绍这些研究中的主要发现,并讨论Pirh 2作为癌症治疗靶点的潜力。
The ubiquitin-dependent proteasome system plays a critical role in many cellular processes and pathogenesis of various human diseases, including cancer. Although there are a large number of E3 ubiquitin ligases, the majority are RING-finger type E3s. Pirh2, a target of p53 transcription factor, contains a highly conserved C3H2C3 type RING domain. Importantly, Pirh2 was found to regulate a group of key factors dedicated to the DNA damage response, such as p53, p73, PolH, and c-Myc. Interestingly, Pirh2 was upregulated or downregulated in different types of cancers. These suggest that Pirh2 is implicated in either promoting or suppressing tumor progression in a tissue-dependent manner. This review will focus on the major findings in these studies and discuss the potential to explore Pirh2 as a cancer therapeutic target.
DOI: 10.1074/jbc.c600147200
发表时间: 2006-11-03
影响因子: 4.8
作者:
Hu, Baoli;Gilkes, Daniele M.;Chen, Jiandong
通讯作者: Chen, Jiandong
DOI: 10.1038/nature02514
发表时间: 2004-05-06
期刊: NATURE
影响因子: 64.8
作者:
Dornan, D;Wertz, I;Dixit, VM
通讯作者: Dixit, VM
DOI: 10.1158/1535-7163.mct-05-0356
发表时间: 2006-02-01
影响因子: 5.7
作者:
Cao, C;Shinohara, ET;Lu, B
通讯作者: Lu, B
DOI: 10.1677/jme.0.0290041
发表时间: 2002-08-01
影响因子: 3.5
作者:
Beitel, LK;Elhaji, YA;Trifiro, MA
通讯作者: Trifiro, MA
DOI: 10.1002/j.1460-2075.1993.tb05678.x
发表时间: 1993-02-01
期刊: EMBO JOURNAL
影响因子: 11.4
作者:
BARAK, Y;JUVEN, T;OREN, M
通讯作者: OREN, M